Dr. Gray comes to Enosi with more than 40 years of experience in the biotech, biochemistry, and molecular biology sectors. During his time in the field, he’s developed over 40 U.S. patents for more than 20 different technologies. His experience and dedication to developing new ways to improve people’s health made him the perfect candidate to advance Enosi’s next generation of autoimmune, cancer and acute inflammation therapies that induce disease regression, and prevent relapse while dramatically reducing patient side effects.
Dr. Gray’s long list of accomplishments includes the first cloning and characterization of the Hepatitis B viral surface antigen. This work led to the development of the HBV vaccine that saves approximately two million lives a year. Dr. Gray’s dedication to drug discovery and saving lives will help provide leadership, direction, and vision to Enosi’s rapidly growing organization.
Before being named Enosi Life Sciences CEO, Dr. Gray served as CEO for Pascal Biosciences (2015-2021) and was CEO of Nura, Inc. (2003-2006). Dr. Gray has had close relationships with Enosi founders, since he began his career in biotechnology in 1980 at Genentech as a coworker of Dr. Shepard, and he was a scientist in Dr. Feldmann’s lab from 1989-1990. Dr. Gray has also received awards and honors throughout his career including a Distinguished Alumni Fellows Award from his alma mater, the University of Oregon. He holds a Ph.D. in Chemistry from the University of Colorado, Boulder, CO.
James N. Woody
Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.
He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA.
Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade.
Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program.
He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service.
Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
H. Michael Shepard, Ph.D.
CEO & Co-founder
Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.
Sir Marc Feldmann, M.D. Ph.D.
Director & Co-founder
Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
Anti-TNF sales > $50B USD globally.
Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.